Promoted Content
Promoted Content

Find Novel Oncology Drugs in Clinical Development in UNITED STATES


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OP-1250,Palbociclib

            Therapeutic Area: Oncology Product Name: OP-1250

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Olema Oncology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 13, 2020


            Olema Oncology will evaluate OP-1250, in combination with Pfizer's IBRANCE® in patients with recurrent, locally advanced or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative breast cancer. Pfizer will supply IBRANCE for the study.